Sam Altman, already having a bad start to his week as a Chinese chatbot has put into doubt the lead of U.S. AI startups, is facing another headache. One of the other startups in his growing empire, World, has reportedly been blocked by Brazilian authorities from paying people to scan their irises into its World ID system.

Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT reports.

Since then, Musk hasn’t hidden his anger with Altman and OpenAI. He’s currently suing the company over its decision to become a for-profit corporation, and he regularly trolls the company on X—the platform he bought for $44 billion back in 2022. All of which is why the past week has been hilarious.

Altman and Musk were OpenAI’s founding co-chairs in 2015, but their relationship has devolved into name-calling and lawsuits.

Elon Musk asked a judge to block OpenAI's attempt to transition from nonprofit to for-profit. It's not the first time he's feuded with CEO Sam Altman.

DeepSeek is a Hangzhou-based startup whose controlling shareholder is Liang Wenfeng, cofounder of quantitative hedge fund High-Flyer, based on Chinese corporate records.

Sam Altman's comments came amid a flurry of online exchanges between himself, Musk, and Microsoft over the $500 billion Stargate Project announced by Trump.

OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI agent that can act

Trump calls Chinese startup DeepSeek's cheaper AI methods "a positive," as U.S. tech stocks plunge amid market sell-off.

DeepSeek’s latest models, created by a small company with limited resources, are already beating many of the leading AI models in the United States.

China's DeepSeek R1 AI model is causing a stir with its low-cost capabilities, challenging U.S. tech industry dominance.